METiS TechBio licenses T-cell engager to Boulevard Bio in potential $1.62 billion deal
Hong Kong-listed Chinese biotech METiS TechBio (HKEX: 7666) has licensed global rights to its preclinical trispecific T-cell engager MTS-128 to Deerfield-backed Boulevard Bio, in a deal potentially worth more than $1.6 billion plus royalties.
Under the agreement, Boulevard receives worldwide rights to develop, manufacture and commercialize MTS-128. METiS will receive $20 million upfront and is eligible for up to $1.6 billion in development, regulatory and commercial milestone payments, as well as tiered royalties on future product sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze